The 8 most recent market catalysts affecting $TLSI, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 23, 2026
Corporate Catalyst
Bullish
Impact 65
TriSalus Secures FDA Clearance For TriNav Advance as Stock Tests Key Support
TriSalus Life Sciences announced FDA 510(k) clearance for its TriNav Advance device, which is a positive development for the company as it expands their product offerings in interv…
Sep 23, 2026
Corporate Catalyst
Bearish
Impact 65
TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine And Other Big Stocks Moving Higher On Wednesday
The filing primarily details several stocks that saw significant gains on a Wednesday, contrasting with a general market downturn. The most impactful event is TriSalus Life Science…
Sep 23, 2026
Corporate Catalyst
Bullish
Impact 75
TriSalus Life Sciences shares are trading higher after the company announced it received FDA 510(k) clearance for TriNav Advance
The FDA 510(k) clearance for TriSalus Life Sciences' TriNav Advance is a significant positive catalyst for the company. This regulatory approval allows the company to market and se…
Sep 23, 2026
Corporate Catalyst
Bullish
Impact 55
HC Wainwright & Co. Maintains Buy on TriSalus Life Sciences, Raises Price Target to $12
HC Wainwright & Co. analyst Swayampakula Ramakanth maintained a 'Buy' rating on TriSalus Life Sciences (TLSI) and raised the price target from $11 to $12. This action signals conti…
Sep 22, 2026
Corporate Catalyst
Bullish
Impact 85
TriSalus Life Sciences shares are trading higher after the company announced it received FDA 510(k) clearance for TriNav Advance
The FDA 510(k) clearance for TriNav Advance is a pivotal moment for TriSalus Life Sciences, as it allows them to market and sell this device, which is likely a significant revenue …
Sep 9, 2026
Corporate Catalyst
Neutral
Impact 65
HC Wainwright & Co. Initiates Coverage On TriSalus Life Sciences with Buy Rating, Announces Price Target of $11
HC Wainwright & Co. initiating coverage on TriSalus Life Sciences with a 'Buy' rating and an $11 price target is a positive development for the company. This action indicates that …
Aug 6, 2026
Corporate Catalyst
Bearish
Impact 55
TriSalus Life Sciences Affirms FY2026 Sales Guidance of $54.000M-$57.000M vs $52.396M Est
TriSalus Life Sciences (TLSI) has filed an 8-K to affirm its fiscal year 2026 sales guidance. The company is maintaining its outlook of $54.0 million to $57.0 million, which is sli…
Aug 6, 2026
Corporate Catalyst
Bearish
Impact 75
TriSalus Life Sciences Q2 EPS $(0.16) Misses $(0.15) Estimate, Sales $11.407M Beat $10.267M Estimate
TriSalus Life Sciences (TLSI) released its Q2 earnings, showing a mixed performance. The company's reported loss of $(0.16) per share missed the analyst consensus of $(0.15), indic…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.